# Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the diagnosis, management, and pathogenesis of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. It covers evidence-based guidelines, cellular and molecular mechanisms of fibrosis, therapeutic translation, treatment trials with drugs like pirfenidone and nintedanib, as well as the role of myofibroblasts and epithelial-mesenchymal transition in lung fibrosis. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10870 |
| Works | 345 |

## Topic papers all

Showing 15 of 345.

- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer](https://scholariq.org/papers/osimertinib-or-platinum-pemetrexed-in-i-egfr-i-t790m-positive-lung-cancer/)
- [Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations](https://scholariq.org/papers/phase-iii-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with/)
- [An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease](https://scholariq.org/papers/an-official-european-respiratory-society-american-thoracic-society-technical/)
- [Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017](https://scholariq.org/papers/prevalence-and-attributable-health-burden-of-chronic-respiratory-diseases-1990/)
- [An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline](https://scholariq.org/papers/an-official-ats-ers-jrs-alat-clinical-practice-guideline-treatment-of-idiopathic/)
- [Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib](https://scholariq.org/papers/kras-mutations-and-primary-resistance-of-lung-adenocarcinomas-to-gefitinib-or/)
- [A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullination](https://scholariq.org/papers/a-new-model-for-an-etiology-of-rheumatoid-arthritis-smoking-may-trigger-hla-dr/)
- [Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis](https://scholariq.org/papers/single-cell-rna-sequencing-reveals-profibrotic-roles-of-distinct-epithelial-and-2/)
- [An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features](https://scholariq.org/papers/an-official-european-respiratory-society-american-thoracic-society-research/)
- [Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease](https://scholariq.org/papers/continuous-intravenous-epoprostenol-for-pulmonary-hypertension-due-to-the/)
- [Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline](https://scholariq.org/papers/diagnosis-and-detection-of-sarcoidosis-an-official-american-thoracic-society/)
- [Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition](https://scholariq.org/papers/multiple-stromal-populations-contribute-to-pulmonary-fibrosis-without-evidence/)

## Topic primary papers

Showing 15 of 131.

- [An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline](https://scholariq.org/papers/an-official-ats-ers-jrs-alat-clinical-practice-guideline-treatment-of-idiopathic/)
- [Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis](https://scholariq.org/papers/single-cell-rna-sequencing-reveals-profibrotic-roles-of-distinct-epithelial-and-2/)
- [An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features](https://scholariq.org/papers/an-official-european-respiratory-society-american-thoracic-society-research/)
- [Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition](https://scholariq.org/papers/multiple-stromal-populations-contribute-to-pulmonary-fibrosis-without-evidence/)
- [Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis](https://scholariq.org/papers/prognostic-significance-of-histopathologic-subsets-in-idiopathic-pulmonary/)
- [Pirfenidone in idiopathic pulmonary fibrosis](https://scholariq.org/papers/pirfenidone-in-idiopathic-pulmonary-fibrosis/)
- [Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population‐based study](https://scholariq.org/papers/incidence-and-mortality-of-interstitial-lung-disease-in-rheumatoid-arthritis-a/)
- [Idiopathic pulmonary fibrosis: Disease mechanisms and drug development](https://scholariq.org/papers/idiopathic-pulmonary-fibrosis-disease-mechanisms-and-drug-development/)
- [Pulmonary fibrosis: patterns and perpetrators](https://scholariq.org/papers/pulmonary-fibrosis-patterns-and-perpetrators/)
- [Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis](https://scholariq.org/papers/single-cell-deconvolution-of-fibroblast-heterogeneity-in-mouse-pulmonary/)
- [Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis](https://scholariq.org/papers/senescence-of-alveolar-type-2-cells-drives-progressive-pulmonary-fibrosis/)
- [Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial](https://scholariq.org/papers/pirfenidone-in-patients-with-progressive-fibrotic-interstitial-lung-diseases/)
- [Epidemiologic Survey of Japanese Patients with Idiopathic Pulmonary Fibrosis and Investigation of Ethnic Differences](https://scholariq.org/papers/epidemiologic-survey-of-japanese-patients-with-idiopathic-pulmonary-fibrosis-and/)
- [<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease](https://scholariq.org/papers/i-muc5b-i-promoter-variant-and-rheumatoid-arthritis-with-interstitial-lung/)
- [Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis](https://scholariq.org/papers/incidence-prevalence-and-clinical-course-of-idiopathic-pulmonary-fibrosis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.